Welcome to the international HTA database

Showing [23371 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial tube feeding in acute pancreatitis]
2021	National Institute for Health and Care Excellence (NICE)	Mogamulizumab for previously treated mycosis fungoides and Sezary syndrome. NICE technology appraisal guidance 754
2021	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Addendum to commission H20-05]
2021	National Institute for Health and Care Excellence (NICE)	Risdiplam for treating spinal muscular atrophy. NICE technology appraisal guidance 755
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Prostate cancer; does the use of fusion biopsy lead to better treatment results compared to the use of conventional diagnostic procedures?]
2021	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Recommendations for the appropriate use of vitamin D tests and supplements in the general population]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pemigatinib (cholangiocarcinoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. NICE technology appraisal guidance 756
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Palliative care screening tools
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Addendum to Commission A20-105]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Procalcitonin for antimicrobial discontinuation in hospitalized adult patients
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Second addendum to commission H20-05]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pain in endometriosis: do other procedures instead of painkillers also help?]
2021	HTA South	[Circadian rhythm lighting in psychiatry, care of the elderly and dementia, and rehabilitation]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Prone positioning of patients on extracorporeal membrane oxygenation (ECMO)
2021	Health Information and Quality Authority (HIQA)	Duration of immunity (protection from reinfection) following SARS-CoV-2 infection
2021	Andalusian Health Technology Assessment Area (AETSA)	[Clinical utility of optical coherence tomography angiography in exudative age-related macular degeneration management]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Beclometasone/formoterol/glycopyrronium (asthma) - Addendum to Commission A21-18]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Multiple sclerosis: does the use of mHealth solutions (e.g. apps) lead to better results in the self-management of those affected?]
2021	NIHR Health Services and Delivery Research programme	Hospital-based specialist palliative care compared with usual care for adults with advanced illness and their caregivers: a systematic review
2021	NIHR Health Technology Assessment programme	Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: thrombotic adverse events with adenovirus vaccines
2021	Andalusian Health Technology Assessment Area (AETSA)	[High intensity focused ultrasound (HIFU) in organ-confined prostate tumors]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Atidarsagene autotemcel/OTL-200 (metachromatic leukodystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	NIHR Health Technology Assessment programme	Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT, DAPT plus an anticoagulant) after coronary interventions in the UK: a population based cohort study The ADAPTT Study
2021	NIHR Health Technology Assessment programme	High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation
2021	Austrian Institute for Health Technology Assessment (AIHTA)	[Process and evaluation of digital health applications in the context of "symptom-checkers"]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabotegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021	NIHR Health Technology Assessment programme	EMPOWER: Early Signs Monitoring to Prevent Relapse and PrOmote Wellbeing, Engagement and Recovery
2021	Norwegian Institute of Public Health (NIPH)	[Natalizumab subcutaneous for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment - health economic evaluation]
2021	Austrian Institute for Health Technology Assessment (AIHTA)	National strategies and programmes for preventing and managing non-communicable diseases in selected countries
2021	Malaysian Health Technology Assessment (MaHTAS)	Targeted therapies in combination with neoadjuvant chemotherapy for HER2-positive breast cancer and economic evaluation
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021	NIHR Health Technology Assessment programme	A tailored, psychological intervention for mild to moderate anxiety or depression in people with chronic obstructive pulmonary disease(COPD) (TANDEM Tailored intervention for ANxiety and DEpression Management in COPD)
2021	Norwegian Institute of Public Health (NIPH)	[Ofatumumab for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment – health economic evaluation]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Tracheostomy or endotracheal tubes and subglottic suctioning
2021	Malaysian Health Technology Assessment (MaHTAS)	Therapeutic drug monitoring (TDM) for anti-tuberculosis
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021	NIHR Health Technology Assessment programme	High Or Low Dose Syntocinon for delay in labour (HOLDS)
2021	NIHR Health Technology Assessment programme	Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users
2021	Health Information and Quality Authority (HIQA)	Review of international ethics frameworks used in policy-making in the context of screening
2021	Malaysian Health Technology Assessment (MaHTAS)	Custodiol HTK as a replacement of blood cardioplegia in cardiac surgery
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Risdiplam (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2021	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Specific rehabilitation interventions for physical impairment to avoid chronification of non-specific back pain in adults]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: efficacy and safety of onasemnogene abeparvovec, nusinersen and risdiplam for the treatment of spinal muscular atrophy]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Prevention of tuberculosis reactivation
2021	Malaysian Health Technology Assessment (MaHTAS)	Mobile C-arm fluoroscopy for cardiothoracic surgery
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021	NIHR Health Technology Assessment programme	Specific versus generic psychological therapy for adolescents with social anxiety disorder: a comparison of Clark & Wells condition-specific cognitive therapy adapted for adolescents, with the generic cognitive behaviour therapy that is currently used in adolescent services
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Opioids for vaso-occlusive crisis in pregnant patients
2021	NIHR Health Technology Assessment programme	Improving continence in children and young people with neurodisability: a systematic review and survey
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Esketamine (depression, acute treatment) - Addendum to Commission A21-25]
2021	Haute Autorite de sante (HAS)	[Remote monitoring of patients with an implantable loop recorder]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: vaccination for women who are pregnant or lactating
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of newborn screening for spinal muscular atrophy]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avelumab (urothelial carcinoma) - Addendum to Commission A21-23]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: management of vaccine-associated thrombotic syndromes
2021	Swiss Federal Office of Public Health (FOPH)	Effectiveness and safety of vitamin B12 tests
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Yttrium-90 microspheres for intermediate- or advanced-stage hepatocellular carcinoma
2021	Malaysian Health Technology Assessment (MaHTAS)	Viscoelastic haemostatic assay for non-cardiac surgery
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for stem cell transplantation - Update of commission V18-02]
2021	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Gender-specific differences in drug effects. Exemplary analysis based on beta-adrenoceptor antagonists as cardiac therapy and antidepressants as psychotropic drugs]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: advisability of using molecular tests to clarify the diagnosis of thyroid nodules with indeterminate cytology]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: efficacy and safety of buprenorphine and methadone for the treatment of opioid use disorder]
2021	Andalusian Health Technology Assessment Area (AETSA)	[Laser interstitial thermal therapy for patients with refractory epilepsy: safety and effectiveness. A systematic review]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: timing of nutrition in acute pancreatitis]
2021	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Smoking bans in public places]
2021	NIHR Health Technology Assessment programme	CONservative TReatment of Appendicitis in Children a randomised controlled Trial CONTRACT (Feasibility study)
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: challenging behaviours - best practices in prevention, assessment and Intervention for people with an intellectual disability, physical disability or autism spectrum disorder]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: care pathways leading to the diagnostic assessment of neurodevelopmental disorders in children 0-7 years old]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional interventions in chronic pancreatitis]
2021	NIHR Health Services and Delivery Research programme	Acute Day Units as Crisis Alternatives to Residential Care AD-CARE
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: oral opioid agonists for the treatment of opioid use disorder]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevance of and indications for submitting surgical specimens to the anatomic pathology laboratory: obstetrics/gynecology and urology]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Abiraterone acetate for metastatic castration-sensitive prostate cancer
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Obinutuzumab (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Remote monitoring programs for cardiac conditions
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: effects of vaccines on fertility and pregnancy outcomes
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevance of and indications for submitting surgical specimens to the anatomic pathology laboratory: general surgery, plastic surgery and dermatology]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Bisphosphonate drugs for the treatment of osteoporosis in post-menopausal women
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Obinutuzumab (follicular lymphoma, after rituximab) - Benefit assessment according to §35a Social Code Book V]
2021	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Radiation exposure by medical X-ray applications]
2021	NIHR Health Technology Assessment programme	Minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair: a multicentre randomised controlled trial (UK Mini Mitral)
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: organization of care and services related to alternate levels of care (ALC)]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: optimal use of immunoglobulins in infectious diseases]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Direct oral anticoagulants for atrial fibrillation [evidence update]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V]
2021	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Music therapy for adolescents with mental and behavioural disorders]
2021	NIHR Health Technology Assessment programme	Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM) trial
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: portrait of the use of home care and support services by people at the end-stages of life in Québec, 2013-2018]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Interventions to address and prevent violence toward health care workers in the emergency department
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide and dexamethasone) - Benefit assessment according to §35a Social Code Book V]
2021	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Sentinel lymph node biopsy in oral cavity carcinoma: clinical effectiveness, safety, and cost-effectiveness]
2021	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Effects of life style changes in persons with prediabetes]
2021	NIHR Health Technology Assessment programme	Understanding health-care outcomes of older people with cognitive impairment and/or dementia admitted to hospital: a mixed-methods study
2021	NIHR Health Technology Assessment programme	Antidepressants to prevent relapse in depression
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Amikacin (Mycobacterium avium complex pulmonary infections)]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Hybrid closed-loop insulin delivery systems for people with Type 1 diabetes